Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of novel agents and intensive therapy for patients with multiple myeloma.

Bone marrow transplantation·2013
Same author

Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).

Hematology (Amsterdam, Netherlands)·2010
Same author

CR represents an early index of potential long survival in multiple myeloma.

Bone marrow transplantation·2009
Same author

Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.

Hematology (Amsterdam, Netherlands)·2007
Same author

International uniform response criteria for multiple myeloma.

Leukemia·2006
Same author

Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Solid tumors in multiple myeloma.

R Stegman, R Alexanian

    Annals of Internal Medicine
    |May 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    This study found that long-term melphalan therapy for multiple myeloma did not increase the risk of developing second solid tumors. The incidence of new cancers in patients was similar to the general population.

    More Related Videos

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    Related Experiment Videos

    Last Updated: Jun 23, 2026

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    Area of Science:

    • Oncology
    • Hematology
    • Cancer Research

    Background:

    • Multiple myeloma is a cancer of plasma cells.
    • Chemotherapy, including melphalan-prednisone combinations, is a standard treatment for multiple myeloma.
    • Concerns exist regarding the long-term effects of chemotherapy, including the risk of secondary malignancies.

    Purpose of the Study:

    • To evaluate the frequency of solid tumors in patients with multiple myeloma treated with melphalan-prednisone.
    • To determine if long-term melphalan therapy contributes to the development of second solid tumors.

    Main Methods:

    • Retrospective analysis of 628 patients with multiple myeloma.
    • Evaluation of patients treated with various melphalan-prednisone combinations.
    • Comparison of second tumor incidence with age- and duration-matched normal populations.

    Main Results:

    • The incidence and diversity of second tumors in patients surviving at least 2 months were similar to the general population.
    • Second tumor diagnoses typically occurred within 2 years of initiating myeloma chemotherapy.
    • No apparent contribution of long-term melphalan therapy to the pathogenesis of second solid tumors was observed.

    Conclusions:

    • Long-term melphalan therapy for multiple myeloma does not appear to increase the risk of developing secondary solid tumors.
    • The risk of second tumors in multiple myeloma patients treated with melphalan-prednisone is comparable to that of the general population.